文档介绍：阿法骨化醇[策划]一、;13(12)::.-IFN/binationTherapyforElderlyPatientsWithChronicHepatitisC::(CHC),eofpegylated-interferon(PEG-IFN)/:ThispilotstudyexploredtheefficacyandsafetyofalfacalcidolasvitaminDsourceinPEG-IFN/:ConsecutivetwentyCHCpatientsaged?-IFN/-weeklead-inoforalalfacalcidolwasconducted,anditwassubsequentlyandconcurrentlyadministeredinPEG-IFN/binationtherapy(vitaminDgroup).Age,gender,andIL28Bgenotype-matchedpatients,whoreceivedPEG-IFN/ribavirinalone,weresavedascontrolgroup(n=15):Subjectsconsistedof14malesand16females,withamedianageof70years(65-78).Theserum25(OH)D3concentrationinfemales(20ng/ml,11-37)wassignificantlylowerthanmales(27ng/mL,13-49)(P=).Sustainedvirologicalresponse(SVR)%(5/15)%(12/15)inthevitaminDgroup,respectively(P=).Whilenosignificantdifferencewasshowninthe(SVR)ratebetweenthetwogroupsamongmales(P=),infemalestheSVRratewassignificantlyhigherinthevitaminDgroup(%,7/8)thanthecontrolgroup(%,2/8)(P=).%(1/13)%(8/13),respectively(P=).Interestingly,infemales,therelapseinthecontrolgroupwasshownin5of7(%),whereasinthevitaminDgrouptherelapseratewasdecreased(1/8,%)(P=).:PEG-IFN/,itantadministrationofalfacalcidolmayleadtoareducedrela